We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Abiomed (ABMD) Posts Upbeat Impella SmartAssist Study Results
Read MoreHide Full Article
Abiomed, Inc. recently announced that a huge study of 356 patients treated with Impella 5.5 through SmartAssist across 16 U.S. and German centers demonstrated a 79% survival rate at explant. Notably, bulk of survivors under treatment recovered their native heart function without requiring further mechanical support or a heart transplant.
This proves to be a major breakthrough for Abiomed’s flagship Impella product line.
More on the Study Results
The study is the first large, multicenter experience investigating survival rates with Impella 5.5, which is equipped with SmartAssist support.
Data from the program was assimilated from the Impella Quality (IQ) database and examination centers with 10 or more patients who underwent treatment with Impella 5.5 via SmartAssist.
Authors of the study inferred that Impella 5.5 with SmartAssist delivers successful clinical and device outcomes, such as 79% overall patient survival rate and 86% survival for cardiomyopathy cardiogenic shock patients. Two other impressive results of this study are 67% survival for AMI cardiogenic shock patients and 68% survival for post cardiotomy cardiogenic shock patients.
Notably, the STS (The Society of Thoracic Surgeons) study presentation offers additional evidence of enhanced outcomes with the usage of Impella 5.5 with SmartAssist. Notably, in 2019, Impella 5.5 with SmartAssist had achieved the U.S. FDA clearance with a maximum level of approval for the safety and efficiency in the cardiogenic shock treatment for up to 14 days.
Recent Developments
In December 2020, management announced two crucial breakthroughs in the development of small-bore access to the Impella heart pump. The Impella ECP (expandable cardiac power) heart pump completed the first stage of its FDA early feasibility study (EFS) and the company secured a FDA 510(k) clearance for the Impella XR sheath.
In the same month, Abiomed announced that it could successfully treat the first two patients in the world with the help of its Breethe OXY-1 System, which is a compact cardiopulmonary bypass system. Notably, the Breethe system expedited early mobilization and physical rehabilitation, which are of utmost importance in patient recovery.
Market Prospects
Per a Grand View Research report, the global cardiovascular devices market is anticipated to see a CAGR of 6.6% over the 2016-2024 forecast period. The rising prevalence of chronic heart diseases and sedentary lifestyles is primarily driving this market. Hence, the study findings come in at an opportune time for Abiomed.
Price Performance
Over the past year, shares of this currently Zacks Rank #3 (Hold) company have gained 87.3% compared with the industry’s growth of 26.9%.
Stocks to Consider
Some better-ranked stocks from the broader medical space are Align
Align Technology has a projected long-term earnings growth rate of 19%.
LHC Group has a projected long-term earnings growth rate of 14.1%.
PerkinElmer has an estimated long-term earnings growth rate of 19.5%.
Legal Marijuana: An Investor’s Dream
Imagine getting in early on a young industry primed to skyrocket from $17.7 billion in 2019 to an expected $73.6 billion by 2027.
Although marijuana stocks did better as the pandemic took hold than the market as a whole, they’ve been pushed down. This is exactly the right time to get in on selected strong companies at a fraction of their value before COVID struck. Zacks’ Special Report, Marijuana Moneymakers, reveals 10 exciting tickers for urgent consideration.
Image: Bigstock
Abiomed (ABMD) Posts Upbeat Impella SmartAssist Study Results
Abiomed, Inc. recently announced that a huge study of 356 patients treated with Impella 5.5 through SmartAssist across 16 U.S. and German centers demonstrated a 79% survival rate at explant. Notably, bulk of survivors under treatment recovered their native heart function without requiring further mechanical support or a heart transplant.
This proves to be a major breakthrough for Abiomed’s flagship Impella product line.
More on the Study Results
The study is the first large, multicenter experience investigating survival rates with Impella 5.5, which is equipped with SmartAssist support.
Data from the program was assimilated from the Impella Quality (IQ) database and examination centers with 10 or more patients who underwent treatment with Impella 5.5 via SmartAssist.
Authors of the study inferred that Impella 5.5 with SmartAssist delivers successful clinical and device outcomes, such as 79% overall patient survival rate and 86% survival for cardiomyopathy cardiogenic shock patients. Two other impressive results of this study are 67% survival for AMI cardiogenic shock patients and 68% survival for post cardiotomy cardiogenic shock patients.
Notably, the STS (The Society of Thoracic Surgeons) study presentation offers additional evidence of enhanced outcomes with the usage of Impella 5.5 with SmartAssist. Notably, in 2019, Impella 5.5 with SmartAssist had achieved the U.S. FDA clearance with a maximum level of approval for the safety and efficiency in the cardiogenic shock treatment for up to 14 days.
Recent Developments
In December 2020, management announced two crucial breakthroughs in the development of small-bore access to the Impella heart pump. The Impella ECP (expandable cardiac power) heart pump completed the first stage of its FDA early feasibility study (EFS) and the company secured a FDA 510(k) clearance for the Impella XR sheath.
In the same month, Abiomed announced that it could successfully treat the first two patients in the world with the help of its Breethe OXY-1 System, which is a compact cardiopulmonary bypass system. Notably, the Breethe system expedited early mobilization and physical rehabilitation, which are of utmost importance in patient recovery.
Market Prospects
Per a Grand View Research report, the global cardiovascular devices market is anticipated to see a CAGR of 6.6% over the 2016-2024 forecast period. The rising prevalence of chronic heart diseases and sedentary lifestyles is primarily driving this market. Hence, the study findings come in at an opportune time for Abiomed.
Price Performance
Over the past year, shares of this currently Zacks Rank #3 (Hold) company have gained 87.3% compared with the industry’s growth of 26.9%.
Stocks to Consider
Some better-ranked stocks from the broader medical space are Align
Technology (ALGN - Free Report) , LHC Group and PerkinElmer , each presently carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Align Technology has a projected long-term earnings growth rate of 19%.
LHC Group has a projected long-term earnings growth rate of 14.1%.
PerkinElmer has an estimated long-term earnings growth rate of 19.5%.
Legal Marijuana: An Investor’s Dream
Imagine getting in early on a young industry primed to skyrocket from $17.7 billion in 2019 to an expected $73.6 billion by 2027.
Although marijuana stocks did better as the pandemic took hold than the market as a whole, they’ve been pushed down. This is exactly the right time to get in on selected strong companies at a fraction of their value before COVID struck. Zacks’ Special Report, Marijuana Moneymakers, reveals 10 exciting tickers for urgent consideration.
Download Marijuana Moneymakers FREE >>